Literature DB >> 26276771

T-lymphoblastic leukemia/lymphoma.

M James You1, L Jeffrey Medeiros2, Eric D Hsi3.   

Abstract

OBJECTIVES: To review important concepts from the 2013 Society for Hematopathology/European Association for Haematopathology Workshop session on T-acute lymphoblastic leukemia/T-lymphoblastic lymphoma (T-ALL/T-LBL).
METHODS: Twenty-one submitted cases are reviewed and summarized, with emphasis on key diagnostic or biologic points, and supplemented with relevant literature citations.
RESULTS: Early T-cell precursor (ETP)-ALL represented about one-third of all cases submitted. It is important to recognize ETP-ALL, because these patients have a poor prognosis if treated with standard therapy. A consensus immunophenotype has been developed to aid in the recognition of these cases. Other cases submitted illustrated rare entities, including two cases of Philadelphia chromosome-positive T-ALL, two cases of T-ALL associated with MYC translocations, and single cases illustrating various diseases. A subset of cases submitted illustrated issues related to differential diagnosis of T-ALL/T-LBL.
CONCLUSIONS: In view of the growing importance of molecular genetic analysis in the diagnosis and prognosis of T-ALL/T-LBL, it is important for pathologists to keep abreast of these developments. Currently, routine histopathology, immunophenotyping, conventional cytogenetic analysis, fluorescence in situ hybridization, and clonality testing are usually adequate to establish the diagnosis. However, as therapies become more targeted, assessment for relevant genetic abnormalities, either through candidate gene or broad-scale unbiased approaches, may become necessary. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Early T-cell precursor; Genetics; Immunophenotype; T-ALL

Mesh:

Year:  2015        PMID: 26276771     DOI: 10.1309/AJCPMF03LVSBLHPJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  24 in total

1.  Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.

Authors:  Zhenyue Hao; Rob A Cairns; Satoshi Inoue; Wanda Y Li; Yi Sheng; François Lemonnier; Andrew Wakeham; Bryan E Snow; Carmen Dominguez-Brauer; Jing Ye; Dana M Larsen; Kimberly S Straley; Erica R Tobin; Rohini Narayanaswamy; Philippe Gaulard; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

2.  Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.

Authors:  Mengping Xi; Shanshan Guo; Caicike Bayin; Sophie Rousseaux; Saadi Khochbin; Jian-Qing Mi; Jin Wang; Lijun Peng; Florent Chuffart; Ekaterina Bourova-Flin
Journal:  Front Med       Date:  2021-10-20       Impact factor: 9.927

Review 3.  New Approaches to Treating Challenging Subtypes of ALL in AYA Patients.

Authors:  Kevin Prescott; Michael Jacobs; Wendy Stock; Joseph Wynne
Journal:  Curr Hematol Malig Rep       Date:  2020-12       Impact factor: 3.952

4.  Morphologic and Immunohistochemical Characterization of Spontaneous Lymphoma/Leukemia in NSG Mice.

Authors:  Heather Tillman; Laura J Janke; Amy Funk; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2019-11-18       Impact factor: 2.221

5.  High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.

Authors:  Nicholas J Short; Hagop Kantarjian; Farhad Ravandi; Marina Konopleva; Nitin Jain; Rashmi Kanagal-Shamanna; Keyur P Patel; Walid Macaron; Tapan M Kadia; Sa Wang; Jeffrey L Jorgensen; Joseph D Khoury; Musa Yilmaz; Partow Kebriaei; Koichi Takahashi; Guillermo Garcia-Manero; Naval Daver; Sean M Post; Xuelin Huang; Steven M Kornblau; Sara Pelletier; Wilmer Flores; Jairo Matthews; Rebecca Garris; Elias Jabbour
Journal:  Blood Adv       Date:  2022-07-12

6.  Harnessing immunotherapy for pediatric T-cell malignancies.

Authors:  Caroline Diorio; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2020-02-27       Impact factor: 5.124

7.  Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines.

Authors:  Jianrong Wu; Huajun Liu; Ge Zhang; Ling Gu; Yanle Zhang; Ju Gao; Yuquan Wei; Zhigui Ma
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

8.  Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia.

Authors:  Ling Gu; Zhihui Yi; Yanle Zhang; Zhigui Ma; Yiping Zhu; Ju Gao
Journal:  Oncotarget       Date:  2017-05-09

9.  Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers.

Authors:  Meng Dong; Xudong Zhang; Zhenzhen Yang; Shaoxuan Wu; Mijing Ma; Zhaoming Li; Yu Chang; Xinhua Wang; Ling Li; Xin Li; Mingzhi Zhang; Qingjiang Chen
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

10.  The Comparative Diagnostic Features of Canine and Human Lymphoma.

Authors:  Davis M Seelig; Anne C Avery; E J Ehrhart; Michael A Linden
Journal:  Vet Sci       Date:  2016-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.